Form 4: ExoZymes Officer Receives Stock Grant and Options
Insider Transaction Report
Damien Perriman, Chief Commercial Officer of ExoZymes Inc., was granted restricted stock and stock options on April 1, 2026, as detailed in a Form 4 filing.
Summary
- Damien Perriman, Chief Commercial Officer of ExoZymes Inc., received a restricted stock grant of 62,759 shares and a stock option grant for 146,437 shares.
- The restricted stock grant has a vesting schedule, with 15,689 shares vesting immediately and the remainder vesting quarterly until April 1, 2029.
- The stock options have an exercise price of $9.49 per share and vest monthly, with 36,609 shares vesting immediately and the remainder vesting until April 1, 2029.
- These transactions were made pursuant to Rule 16b-3 of the Securities Exchange Act of 1934.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it details standard executive compensation transactions rather than significant financial performance or strategic shifts.
Positives
- Grant of restricted stock and stock options indicates management's continued commitment and alignment with shareholder interests.
- Immediate vesting of a portion of both the restricted stock and stock options provides immediate incentive and potential upside for the executive.
Future Outlook
The vesting schedules for both the restricted stock and stock options extend through April 1, 2029, indicating a long-term incentive structure for the Chief Commercial Officer.
Industry Context
StockSavvy.ai notes that grants of stock options and restricted stock are common executive compensation tools in the biotechnology and life sciences sector, used to attract, retain, and incentivize key personnel by aligning their financial interests with the company's performance and stock price appreciation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Transaction Compliance | Transactions made pursuant to Rule 16b-3 of Section 16 of the Securities Exchange Act of 1934, as amended. | 04/01/2026 | Ensures compliance with regulatory requirements for insider transactions, providing a safe harbor for the reporting person. |
Stakeholder Impact
- Shareholders: The grants align executive incentives with long-term company performance and stock value, potentially benefiting shareholders if the company's stock price increases.
- Employees: Standard executive compensation practices can influence overall employee morale and retention, though this specific filing pertains only to an executive.
Next Steps
- Continued vesting of restricted stock and stock options according to the outlined schedules.
- Potential exercise of stock options by Damien Perriman as they become vested and exercisable.
Key Dates
| Date | Description |
|---|---|
| 04/01/2026 | Date of earliest transaction; Restricted Stock Grant and Stock Option Grant. |
| 04/01/2029 | Final vesting installment for restricted stock and stock options. |
| 04/12/2033 | Expiration date for stock options. |
| 04/08/2026 | Date of signature on the Form 4 filing. |
Keywords
Form 4, SEC Filing, ExoZymes Inc., EXOZ, Stock Options, Restricted Stock, Insider Trading, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.